Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated Neurocognitive Measurements in Depressed Patients
NCT05991232Phase 2Withdrawn
- Start
- May 2025
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ketamine in major depressive disorder (MDD). Planned start May 2025; status: withdrawn.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05991232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05991232.